ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile idiopathic arthritis (JIA)"

  • Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium

    Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis

    Alexandra Munroe1, Adam Huber 2, Bianca Lang 3, Suzanne Ramsey 4 and Elizabeth Stringer 4, 1Dalhousie University, Halifax, Nova Scotia, Canada, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3Dalhousie University - Halifax, Halifax, Canada, 4IWK Health Centre, Halifax, Canada

    Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
  • Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium

    Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort

    Tara McGrath1, Jaime Guzman 2, Lori Tucker 3, Natalie Shiff 4, Maryna Yaskina 5, Susan Tupper 6 and Dax Rumsey 7, 1University of British Columbia, Vancouver, Canada, 2University of British Columbia and BC Children's Hospital, Vancouver, Canada, 3BC Children's Hospital, Vancouver, British Columbia, Canada, 4Florida, Gainesville, 5Women and Children's Research Institute, Edmonton, Canada, 6Saskatoon, Canada, 7University of Alberta, Edmonton, Canada

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
  • Abstract Number: 181 • 2020 Pediatric Rheumatology Symposium

    Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis

    Sabrina Cavallo1, 1University of Montreal, Montreal, Canada

    Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) can be difficult and lead to undesirable outcomes in terms of socio-professional…
  • Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium

    Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile

    Sara Concha1, Pamela Morales 2, Eduardo Talesnik 1 and Arturo Borzutzky 1, 1Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, 2Department of Pediatric, Clinica Las Condes, Santiago, Chile

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
  • Abstract Number: 115 • 2020 Pediatric Rheumatology Symposium

    Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study

    Kimberly Lewis1, Nico Osier 2, Patricia Carter 3, Christina Nguyen 4, Ruy Carrasco 5, Shelby Brooks 2, Alexandra Garcia 6 and Stefano Tiziani 5, 1The University of Texas at Austin, Austin, Texas, 2The University of Texas at Austin, Austin, 3University of Alabama, Tuscalossa, 4Ascension Seton Nursing Research, Austin, 5The University of Texas at Austin, Dell Medical School, Austin, 6The University of Texas at Austin, Dell Medical School, School of Nursing, Austin

    Background/Purpose: The purpose of this study is to define the relationships between pain and carbohydrate metabolism in teens with active juvenile idiopathic arthritis (JIA), teens…
  • Abstract Number: 182 • 2020 Pediatric Rheumatology Symposium

    Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood

    Sabrina Cavallo1, 1University of Montreal, Montreal, Canada

    Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) may be a difficult period with challenges in socio-professional integration and in…
  • Abstract Number: 047 • 2020 Pediatric Rheumatology Symposium

    Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts

    Yongdong Zhao1, Timothy Beukelman 2, Yukiko Kimura 3, Mara Becker 4, Sarah Ringold 5, Anne Dennos 6 and Laura Schanberg 7 for the CARRA investigators, 1University of Washington, Seattle, 2University of Alabama at Birmingham, Birmingham, 3Hackensack Meridian School of Medicine, Hackensack, 4Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, 5Seattle Children's, Seattle, 6Duke University, Durham, 7Duke University Hospital, DURHAM

    Background/Purpose: In July 2015, the CARRA Registry was re-established as a multi-center observational study that collects essential data from patients with childhood-onset rheumatic diseases. The…
  • Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium

    Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry

    Natalie Shiff1, Aimee Lougee 2, Roland Matsouaka 2, David Collier 3, Yukiko Kimura 4, Dax Rumsey 5, Jennifer Schenfeld 6, Scott Stryker 7, Marinka Twilt 8 and Timothy Beukelman 9, 1Florida, Gainesville, 2Duke University, Durham, 3Amgen, Thousand Oaks, 4Hackensack Meridian School of Medicine, Hackensack, 5University of Alberta, Edmonton, Canada, 6Amgen, Long Beach, 7Amgen, Inc, San Francisco, 8Alberta Children's Hospital, Calgary, Canada, 9University of Alabama at Birmingham, Birmingham

    Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
  • Abstract Number: 184 • 2020 Pediatric Rheumatology Symposium

    A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents

    Ashley Cooper1, Elaine Flanagan 2, Tova Ronis 3, Baruch Goldberg 4, Ashley Sherman 1, Chelsey Smith 5 and Gary Holland 6 for the CARRA investigators, 1Children's Mercy Kansas City, Kansas City, 2Emory University, Atlanta, 3Children's National Hospital, Washington, 4UT Physicians, Houston, 5Children's Mercy Kansas City, Holden, 6

    Background/Purpose: Chronic anterior uveitis is a sight-threatening complication of juvenile idiopathic arthritis (JIA).  Prompt treatment to prevent complications requires regular screening and detection of uveitis…
  • Abstract Number: 048 • 2020 Pediatric Rheumatology Symposium

    Novel Algorithm to Increase Sensitivity of Detecting Active Arthritis in Children Through Infrared Thermal Imaging

    Yongdong Zhao1, Ramesh Iyer 1, Mahesh Thapa 1, Debosmita Biswas 1, Kevin Cain 1, Savannah Partridge 1 and Carol Wallace 1, 1University of Washington, Seattle

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. The use of infrared thermal imaging for screening JIA has not utilized…
  • Abstract Number: 121 • 2020 Pediatric Rheumatology Symposium

    Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis

    Emily Liebling1, Walter Faig 2, Nicholas Moore 1, Nahomy Ledesma Vicioso 3 and Melissa Lerman 4, 1Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 2Children's Hospital of Philadelphia, Philadelphia, 3Weill Cornell Medical College, New York, New York, 4Philadelphia, Pennsylvania

    Background/Purpose: JIA – associated uveitis (JIA-U) accounts for 20-40% of childhood noninfectious uveitis and affects 10-20% of patients with JIA. Its chronic course is often…
  • Abstract Number: 186 • 2020 Pediatric Rheumatology Symposium

    Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases

    Lucila Pereira1, Agatha Nogueira Previdelli 2, Rosana Gomes de Torres Rossi 2, Wellington Douglas Rodrigues 3, Fernado Luiz Affonso Fonseca 3, Claudio Len 4, Roseli Oselka Saccardo Sarni 3 and Maria Teresa Terreri 4, 1Federal University of Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 2Sao Judas Tadeu University, Sao Paulo, Brazil, 3Federal University of Sao Paulo, Sao Paulo, Brazil, 4Sao Paulo, Brazil

    Background/Purpose: Chronic rheumatic diseases in children and adolescents increase cardiovascular risk. Thus, knowing the eating habits, biomarkers of lipid metabolism and the lifestyle of patients…
  • Abstract Number: 049 • 2020 Pediatric Rheumatology Symposium

    Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures

    Danielle Fair1, Judyann Olson 2, Jan Lemke 3, Stella Protopapas 4, Ke Yan 5 and Jian Zhang 6, 1Medical College of Wisconsin & Affiliated Hospitals: Children's Wisconsin, Wauwatosa, Wisconsin, 2Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, 3Children's Wisconsin, Milwaukee, Wisconsin, 4Riley Children’s Hospital at Indiana University, Indianapolis, Indiana, 5Medical College of Wisconsin, Milwaukee, Wisconsin, 6Medical College of Wisconsin, 53226, Wisconsin

    Background/Purpose: Children with chronic diseases have higher rates of mental health issues and less favorable outcomes than the general pediatric population.  Children with JIA experience…
  • Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium

    Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center

    Sarah Kodama1, Deepti Gupta 2, Erin Sullivan 3 and Yongdong Zhao 4, 1School of Medicine, Virginia Commonwealth University, Richmond, 2Pediatric Dermatology, School of Medicine, University of Washington, Seattle, 3Seattle Children's Research Institute, Seattle, 4University of Washington, Seattle

    Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
  • Abstract Number: 053 • 2020 Pediatric Rheumatology Symposium

    Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis

    Karine Toupin April1, Adam Huber 2, Ciaran Duffy 3, Deema Couchman 1, Laurie Proulx 4, Esi Morgan 5, Fjolla Berbatovci 1, Andrea Boyd 1, Hannah Sachs 1, Alexandra Sirois 6, Lucie Brosseau 3, Janice Cohen 7, Margaret Bisch 3, Aditi Sivakumar 1, Marco Ragusa 1, Tania El Hindi 8, Isabelle Gaboury 9, Linda Li 10, Elizabeth Stringer 11, France Legare 12, Sabrina Cavallo 13, Michele Gibbon 14, Paul Fortin 15, William Brinkman 5, Mark Connelly 16, Jennifer Weiss 17, Sabrina Gmuca 18, Peter Tugwell 19 and Jennifer Stinson 20, 1Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada, 2IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, 3Ottawa, Canada, 4Canadian Arthritis Patient Alliance, Ottawa, Canada, 5Cincinnati Children's Hospital, Cincinnati, 6Outremont, Canada, 7Children's Hospital of Eastern Ontario, Ottawa, Canada, 8Statistics Canada, Ottawa, Canada, 9University of Sherbrooke, Sherbrooke, Canada, 10University of British Columbia, Vancouver, Canada, 11IWK Health Centre, Halifax, Canada, 12Laval University, Quebec City, Canada, 13University of Montreal, Montreal, Canada, 14Children's Hospital of Eastern Ontario RI, Ottawa, Canada, 15CHU de Quebec - Universite Laval, Quebec, Canada, 16Kansas City, 17Hackensack University Medical Center, Hackensack, 18Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19University of Ottawa - Ottawa, Ottawa, Canada, 20University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada

    Background/Purpose: Although juvenile idiopathic arthritis (JIA) is one of the most common causes of chronic musculoskeletal pain among youth, families’ decision-making for pain management is…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology